Cosentyx is a medication used to treat various inflammatory conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. The active ingredient in Cosentyx is secukinumab, which works by blocking the activity of a protein called interleukin-17A that is involved in the inflammation process [1].

While there is limited information available on the specific benefits of Cosentyx for elderly patients, a study published in the Journal of the American Academy of Dermatology found that the medication was generally well-tolerated and effective in treating moderate to severe psoriasis in patients aged 65 and older [2]. The study also noted that the safety profile of Cosentyx was consistent with previous studies in younger patients.

In addition to its effectiveness in treating inflammatory conditions, Cosentyx offers a personal support program called Cosentyx Connect. This program provides resources and support for patients, including financial assistance, nurse support, and educational materials [3].

It is important to note that, like all medications, Cosentyx may not be appropriate for every patient, and individual results may vary. Patients should consult with their healthcare provider to determine if Cosentyx is a suitable treatment option for their specific condition and medical history.

Sources:
[1] DrugPatentWatch. Cosentyx. https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX. Accessed 13 Oct 2021.
[2] Lebwohl MG, et al. Secukinumab is effective and has a favorable safety profile in elderly patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2018;79(4):650-657.e1. doi: 10.1016/j.jaad.2018.05.027. PMID: 29857024.
[3] Cosentyx. Cosentyx Connect. https://www.cosentyx.com/cosentyx-connect-personal-support-program. Accessed 13 Oct 2021.